Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Leukocyte cell therapy - Enlivex Therapeutics

Next Previous
Drug Profile

Leukocyte cell therapy - Enlivex Therapeutics

Alternative Names: Allocetra; Allocetra-OTS; OTS-Allocetra

Latest Information Update: 16 Sep 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Hadassah Medical Organization
  • Developer Enlivex Therapeutics; Hadassah Medical Organization
  • Class Antineoplastics; Cell therapies; Immunotherapies
  • Mechanism of Action Leukocyte replacements; Macrophage modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Graft-versus-host disease
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Graft-versus-host disease; Inflammation; Lung disorders; Multiple organ failure; Osteoarthritis; SARS-CoV-2 acute respiratory disease
  • Phase I Psoriatic arthritis
  • No development reported Crohn's disease; Gout; Multiple sclerosis; Rheumatoid arthritis; Transplant rejection
  • Discontinued COVID 2019 infections; Mesothelioma; Peritoneal cancer; Solid tumours

Most Recent Events

  • 11 Sep 2025 Efficacy and adverse events data from a phase IIa part of I/II trial in Osteoarthritis released by Enlivex
  • 11 Sep 2025 Enlivex Therapeutics plans a phase III trial in Osteoarthritis
  • 09 Sep 2025 Enlivex Therapeutics has patent protection for AllocetraTM in Israel

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top